|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
PT2529020T
(pt)
*
|
2010-01-28 |
2018-07-30 |
Childrens Hospital Philadelphia |
Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica
|
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP3514232A1
(en)
|
2010-04-23 |
2019-07-24 |
University of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
CA2847604A1
(en)
*
|
2011-09-08 |
2013-03-14 |
Uniqure Ip B.V. |
Removal of contaminating viruses from aav preparations
|
|
US20150320799A1
(en)
|
2012-12-20 |
2015-11-12 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
FR3002237B1
(fr)
*
|
2013-02-15 |
2017-12-15 |
Genethon |
Methodes pour la production de particules virales aav double brin
|
|
EP3074510B1
(en)
|
2013-11-26 |
2018-08-01 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Adeno-associated virus vectors for treatment of glycogen storage disease
|
|
GB201401707D0
(en)
|
2014-01-31 |
2014-03-19 |
Sec Dep For Health The |
Adeno-associated viral vectors
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
DK3119797T3
(da)
|
2014-03-18 |
2021-03-15 |
Univ Massachusetts |
Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
|
|
ES2760263T3
(es)
*
|
2014-03-21 |
2020-05-13 |
Genzyme Corp |
Tratamiento génico de la retinitis pigmentaria
|
|
WO2015164778A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennysylvania |
Ldlr variants and their use in compositions for reducing cholesterol levels
|
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
RU2020140209A
(ru)
|
2014-10-21 |
2021-01-25 |
Юниверсити Оф Массачусетс |
Варианты рекомбинантных aav и их применения
|
|
HK1244849B
(en)
*
|
2014-11-28 |
2020-04-09 |
Uniqure Ip B.V. |
Dna impurities in a composition comprising a parvoviral virion
|
|
CA2972038C
(en)
|
2014-12-23 |
2023-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adeno-associated virus vectors encoding modified g6pc and uses thereof
|
|
WO2016114992A2
(en)
|
2015-01-13 |
2016-07-21 |
Alfa Wassermann, Inc. |
Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) and gradients and flow-through buffers therefore
|
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
|
EP3054006A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
|
|
EP3256170B1
(en)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
US20180245073A1
(en)
*
|
2015-02-23 |
2018-08-30 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
US10058624B2
(en)
|
2015-04-16 |
2018-08-28 |
Emory University |
Recombinant promoters and vectors for protein expression in liver and use thereof
|
|
BR112017022621A2
(pt)
|
2015-04-23 |
2018-07-17 |
Baker Idi Heart And Diabetes Inst |
liberação do gene de smad7 como uma substância terapêutica
|
|
WO2016172008A1
(en)
|
2015-04-24 |
2016-10-27 |
University Of Massachusetts |
Modified aav constructions and uses thereof
|
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
CA3002982A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
CN105420275A
(zh)
*
|
2015-11-27 |
2016-03-23 |
中国科学院苏州生物医学工程技术研究所 |
制备外源功能基因定点整合的人神经干细胞的方法
|
|
EP3400304B1
(en)
|
2015-12-11 |
2022-04-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
WO2017100674A1
(en)
*
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
WO2017100704A1
(en)
*
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
|
ES2934848T3
(es)
|
2015-12-11 |
2023-02-27 |
Univ Pennsylvania |
Método de purificación escalable para AAV8
|
|
WO2017160360A2
(en)
|
2015-12-11 |
2017-09-21 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav9
|
|
ES2983043T3
(es)
|
2015-12-18 |
2024-10-21 |
Sangamo Therapeutics Inc |
Alteración dirigida del receptor de células T
|
|
CN108699132B
(zh)
|
2015-12-18 |
2023-08-11 |
桑格摩生物治疗股份有限公司 |
Mhc细胞受体的靶向破坏
|
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
|
US10724020B2
(en)
|
2016-02-02 |
2020-07-28 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
|
IL300254B2
(en)
|
2016-02-05 |
2025-06-01 |
Univ Emory |
Administration of single stranded or self-complementary adeno-associated virus 9 by injection into the cerebrospinal fluid to target gene therapy to the central nervous system
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
PH12018502104B1
(en)
*
|
2016-03-31 |
2024-03-27 |
Spark Therapeutics Inc |
Column-based fully scalable raav manufacturing process
|
|
WO2017176929A1
(en)
|
2016-04-05 |
2017-10-12 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
GB201612248D0
(en)
|
2016-07-14 |
2016-08-31 |
Puridify Ltd |
New process
|
|
DK3488007T3
(da)
*
|
2016-07-21 |
2024-02-19 |
Spark Therapeutics Inc |
Skalerbare fremgangsmåder med høj indvinding til fremstilling af højt udbytte rekombinant adeno-associeret viral (raav) vektor og rekombinante adeno-associeret virale (raav) vektorer produceret derved
|
|
US11883470B2
(en)
|
2016-07-25 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
EP3510161A4
(en)
|
2016-08-23 |
2020-04-22 |
Akouos, Inc. |
COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT
|
|
US10975393B2
(en)
|
2016-08-24 |
2021-04-13 |
Sangamo Therapeutics, Inc. |
Engineered target specific nucleases
|
|
SG11201901531TA
(en)
|
2016-08-24 |
2019-03-28 |
Sangamo Therapeutics Inc |
Regulation of gene expression using engineered nucleases
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
MX2019004784A
(es)
|
2016-11-04 |
2019-08-12 |
Baxalta Inc |
Metodos de purificacion del virus adeno-asociado.
|
|
EP3321357A1
(en)
|
2016-11-09 |
2018-05-16 |
Deutsches Krebsforschungszentrum |
Scalable process for oncolytic rat parvovirus h-1 production and purification based on isoelectric point-based elimination of empty particles
|
|
WO2018140946A1
(en)
|
2017-01-30 |
2018-08-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant virus vectors for the treatment of glycogen storage disease
|
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
|
|
US11554147B2
(en)
|
2017-02-20 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
JP7327803B2
(ja)
|
2017-05-09 |
2023-08-16 |
ユニバーシティ オブ マサチューセッツ |
筋萎縮性側索硬化症（ａｌｓ）を処置する方法
|
|
JP2020519272A
(ja)
|
2017-05-09 |
2020-07-02 |
エモリー ユニバーシティー |
凝固因子変異体及びその使用
|
|
BR112019025792A2
(pt)
|
2017-06-07 |
2020-07-07 |
Spark Therapeutics, Inc. |
agentes de aperfeiçoamento para transfecção de células melhoradas e/ou produção de vetor raav
|
|
CA3068622A1
(en)
*
|
2017-06-30 |
2019-01-03 |
Spark Therapeutics, Inc. |
Aav vector column purification methods
|
|
CN111448321A
(zh)
|
2017-09-22 |
2020-07-24 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
EP3697916A4
(en)
|
2017-10-20 |
2021-08-11 |
Research Institute at Nationwide Children's Hospital |
METHODS AND MATERIALS FOR NT-3 GENE THERAPY
|
|
CN120505370A
(zh)
*
|
2017-11-08 |
2025-08-19 |
诺华股份有限公司 |
制备病毒载体的手段和方法及其用途
|
|
AU2019209432A1
(en)
|
2018-01-22 |
2020-08-06 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for CAR T cells
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
BR112020015798A2
(pt)
|
2018-02-01 |
2021-03-09 |
Homology Medicines, Inc. |
Composições de vírus adeno-associado para restaurar função de gene da pah e métodos de uso das mesmas
|
|
CN111936518A
(zh)
|
2018-02-06 |
2020-11-13 |
西雅图儿童医院（Dba西雅图儿童研究所） |
对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
|
|
JP7244547B2
(ja)
|
2018-02-19 |
2023-03-22 |
ホモロジー・メディシンズ・インコーポレイテッド |
Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
|
|
WO2019165237A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
EP3758736B1
(en)
|
2018-03-02 |
2024-05-01 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Il-34 for use in a method of treating retinal inflammation and neurodegeneration
|
|
AU2019247866A1
(en)
*
|
2018-04-05 |
2020-10-22 |
Nightstarx Limited |
AAV compositions, methods of making and methods of use
|
|
EP3801638A1
(en)
|
2018-06-08 |
2021-04-14 |
Novartis AG |
Cell-based assay for measuring drug product potency
|
|
EP3802829A4
(en)
|
2018-06-08 |
2022-10-19 |
University of Massachusetts |
ANTISENSE OLIGONUCLEOTIDES TO RESTORE DYSFERLIN PROTEIN EXPRESSION IN CELLS FROM PATIENTS WITH DYSFERLINOPATHY
|
|
AU2019296451B2
(en)
|
2018-06-29 |
2021-04-29 |
Wuhan Neurophth Biotechnology Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
|
SG11202101032VA
(en)
|
2018-08-20 |
2021-02-25 |
Wuhan Neurophth Biotechnology Ltd Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
|
EP3852911B1
(en)
|
2018-09-21 |
2025-01-22 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
BR112021009739A2
(pt)
*
|
2018-11-30 |
2021-10-19 |
Novartis Ag |
Vetores virais aav e usos dos mesmos
|
|
CN113454226B
(zh)
|
2018-12-18 |
2025-10-31 |
阿尔特拉吉尼克斯制药公司 |
用于治疗糖原贮积病的方法和组合物
|
|
WO2020142653A1
(en)
|
2019-01-04 |
2020-07-09 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy constructs for treating wilson disease
|
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
CN113631225A
(zh)
*
|
2019-01-18 |
2021-11-09 |
沃雅戈治疗公司 |
用于生产aav颗粒的方法和系统
|
|
WO2020264254A1
(en)
|
2019-06-28 |
2020-12-30 |
Crispr Therapeutics Ag |
Materials and methods for controlling gene editing
|
|
EP4004213A1
(en)
|
2019-07-25 |
2022-06-01 |
Novartis AG |
Regulatable expression systems
|
|
WO2021062012A1
(en)
|
2019-09-25 |
2021-04-01 |
Emory University |
Use of klk10 and engineered derivatizations thereof
|
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
|
WO2021124152A1
(en)
|
2019-12-19 |
2021-06-24 |
Pfizer Inc. |
Compositions and methods for nucleic acid transfection using cationic polymers and stabilizers
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
WO2021146625A1
(en)
|
2020-01-17 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Gene therapy for treatment of crx-autosomal dominant retinopathies
|
|
IL294781A
(en)
|
2020-02-14 |
2022-09-01 |
Ultragenyx Pharmaceutical Inc |
Gene therapy for treating cdkl5 deficiency disorder
|
|
WO2021168362A1
(en)
|
2020-02-21 |
2021-08-26 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
MX2023000614A
(es)
|
2020-07-16 |
2023-02-13 |
Acuitas Therapeutics Inc |
Lipidos cationicos para usarse en nanoparticulas lipidicas.
|
|
US20230294017A1
(en)
*
|
2020-08-18 |
2023-09-21 |
Sartorius Bia Separations D.O.O. |
Multimodal metal affinity processing aav capsids
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
CA3197730A1
(en)
|
2020-10-15 |
2022-04-21 |
F. Hoffman-La Roche Ag |
Nucleic acid constructs for va rna transcription
|
|
AU2021363098A1
(en)
|
2020-10-15 |
2023-05-18 |
F. Hoffmann-La Roche Ag |
Nucleic acid constructs for simultaneous gene activation
|
|
CN117980484A
(zh)
|
2021-09-16 |
2024-05-03 |
诺华股份有限公司 |
新颖的转录因子
|
|
IL313486A
(en)
|
2021-12-16 |
2024-08-01 |
Acuitas Therapeutics Inc |
Lipids for use in lipid nanoparticle formulations
|
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
|
WO2023198685A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Method for determining aav genomes
|
|
US20250353883A1
(en)
|
2022-05-06 |
2025-11-20 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
|
CN119256220A
(zh)
|
2022-05-23 |
2025-01-03 |
豪夫迈·罗氏有限公司 |
用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法
|
|
EP4532737A1
(en)
|
2022-06-03 |
2025-04-09 |
F. Hoffmann-La Roche AG |
Method for producing recombinant aav particles
|
|
WO2024013239A1
(en)
|
2022-07-14 |
2024-01-18 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant aav particles
|
|
CA3264505A1
(en)
|
2022-09-12 |
2024-03-21 |
Hoffmann La Roche |
METHOD FOR SEPARING SOLID AND EMPTY VAA PARTICLES
|
|
IL322001A
(en)
|
2023-02-07 |
2025-09-01 |
Hoffmann La Roche |
Method for detecting antibodies to anti-AAV particles
|
|
WO2024168358A1
(en)
|
2023-02-10 |
2024-08-15 |
Expression Therapeutics, Llc |
Lentiviral system
|
|
WO2024178113A1
(en)
|
2023-02-22 |
2024-08-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recombinant adeno-associated virus vectors lacking an immunodominant t cell epitope and use thereof
|
|
WO2024196814A1
(en)
|
2023-03-17 |
2024-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for treatment of age-related macular degeneration
|
|
AU2024239386A1
(en)
|
2023-03-21 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for the production of recombinant aav particle preparations
|
|
WO2025090942A1
(en)
*
|
2023-10-26 |
2025-05-01 |
University Of Notre Dame Du Lac |
Gene therapy for treatment of neurometabolic disease
|
|
WO2025168663A1
(en)
|
2024-02-09 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant adeno-associated viral particles
|